Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Omega-3s: gene test could predict heart benefits

NCT ID NCT01343342

Knowledge-focused Sponsor: Laval University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 04, 2026 · Updated 2 times

Summary

This study looks at whether genetic differences affect how omega-3 supplements influence heart disease risk factors like cholesterol and blood pressure. Researchers are giving 200 healthy adults omega-3 capsules daily and measuring changes in blood lipids, blood pressure, and gene activity. The goal is to understand why some people may benefit more from omega-3s than others.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
omega-3 fatty acid supplements (EPA and DHA)
What this could lead to
If successful, this could help personalize dietary advice for heart health based on a person's genes.
What could go wrong
This is an observational study, not a treatment trial. Results may not lead to any direct health changes or apply to everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Oct 2009

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 50 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * healthy men and women aged between 18 to 50 years; * having a BMI between 25 and 40kg/m2; * plasma triglycerides levels \<4.0 mmol/L; * non-smokers; * free of any thyroid or metabolic disorders requiring treatment such as diabetes, hypertension, severe dyslipidemia, and coronary heart disease. Exclusion Criteria: * subjects taking medication for hyperlipidemia, hypertension, diabetes or taking anticoagulant or n-3 PUFA supplementation; * having a taste aversion for fish, fish allergy or regular alcohol drinker; * body mass index \> 40kg/m2; * pregnant or nursing women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cardiovascular disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiovascular disease

Contacts and locations

Locations

  • Institute of Nutraceutical and Functional Foods (INAF), Laval University

    Québec, G1V0A6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.